Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Bera Website

Tapan K. Bera, Ph.D

Portait Photo of Tapan Bera
Laboratory of Molecular Biology
Molecular Biology Section
Associate Scientist
Center for Cancer Research
National Cancer Institute
Building 37, Room 5110
Bethesda, MD 20892


Dr. Bera received his M.S. and Ph.D. in biochemistry from the Calcutta University, India. He completed his postdoctoral training at the Cancer Research Laboratory, University of California-Berkeley and at the Laboratory of Molecular Biology, Center for Cancer Research, NCI. Currently, Dr. Bera is an associate scientist.


My research goals and objectives are focused mainly on understanding the molecular basis of cancer by identifying the genes involved in this process and translating this information for possible targeted therapy of cancer.

Identification of molecular targets for immuno-based therapy of cancer. Expressed sequence tags (EST) are sequences derived from randomly selected clones from various cDNA libraries. Each cDNA clone is generated from a transcript and the frequency and distribution of the many different transcripts in any given tissue depends on the tissue specific activity of genes. Therefore ESTs provide a valuable source of information that may be utilized to predict the expression patterns of certain genes in different tissues. There are many ways by which the vast amount of EST sequence data can be processed to cluster, sort and filter the cDNA sequences, with the goal to identify genes that are specifically expressed in certain tissues. Using various bioinformatics tools in combination with experimental verification, we have identified several new genes, which are specifically expressed in prostate cancer and in normal prostate but not in essential tissue. NGEP is a new gene encoding plasma membrane protein specifically expressed in normal prostate and prostate cancer. Because of its restricted expression in prostate cancer and encoding a plasma membrane protein NGEP is a promising molecular target for immuno-based therapy of prostate cancer and we are in the process of developing monoclonal antibodies to NGEP and eventually will develop immunotoxin targeting prostate cancer.

New model for obesity and gigantism due to disruption of the Ankrd26 gene. During our effort to identify cancer specific membrane protein as immuno-based therapeutic target, we have identified a primate-specific gene family POTE. Although POTE protein is associated with inner membrane of the cell it is not an integral membrane protein and thus not an ideal candidate for immuno-based targeted therapy. Expression of POTE gene is restricted to a very few normal tissues but its expression is induced in various cancers suggesting a role in cancer. To gain some insight on the biological function of POTE gene family, we have identified the POTE ancestor gene ANKRD26, and its mouse ortholog. By 'Gene knock-out' approach, we have generated a mutant mice with inactivation of Ankdr26 protein. Homozygous Ankrd26 mutant mice with partial inactivation of the protein develop extreme obesity and an increase in organ and body size. In future we would like to utilized 'conditional gene targeting' approach to generate tissue specific knock-out of Ankrd26 gene to understand its function in different organs. Ankrd26 gene is expressed in many adult organs as well as during embryogenesis. Several organs including heart, liver and kidney grow larger due to partial inactivation of Ankrd26 gene. We would like to study the role of Ankrd26 on normal development as well as in carcinogenesis process for these organs in tissue specific null mice.

This page was last updated on 7/11/2014.